gsk343 has been researched along with benzyloxycarbonylleucyl-leucyl-leucine-aldehyde* in 1 studies
1 other study(ies) available for gsk343 and benzyloxycarbonylleucyl-leucyl-leucine-aldehyde
| Article | Year |
|---|---|
Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
The endoplasmic reticulum kinase inositol-requiring enzyme 1 (IRE1) and its downstream target X-box-binding protein 1 (XBP1) drive B-cell differentiation toward plasma cells and have been shown to contribute to multiple myeloma development; yet, little is known of the role of this pathway in diffuse large B-cell lymphoma (DLBCL). Here, we show that in the germinal center B-cell-like (GCB) DLBCL subtype, IRE1 expression is reduced to a level that prevents XBP1 activation. Gene expression profiles indicated that, in GCB DLBCL cancer samples, expression of Topics: Animals; B-Lymphocytes; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Endoribonucleases; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Germinal Center; Histones; Humans; Indazoles; Leupeptins; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, 129 Strain; Plasma Cells; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Pyridones; RNA, Messenger; Signal Transduction; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2017 |